Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. (Q54577077)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

author name string

Hideaki Tokiniwa

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

Jun Horiguchi

2

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

Daisuke Takata

3

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

Mami Kikuchi

4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

Nana Rokutanda

5

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

Rin Nagaoka

6

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

Ayako Sato

7

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

Hiroki Odawara

8

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

Katsunori Tozuka

9

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

Tetsunari Oyama

10

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

Izumi Takeyoshi

11

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

publication date

2 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

19

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

309-314

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

Effect of screening and adjuvant therapy on mortality from breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Human cells express two differentially spliced forms of topoisomerase II beta mRNA

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Biochemical basis for the interactions of type I and type II topoisomerases with DNA.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Prognostic value of Ki-67 immunolabelling in primary operable breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Differential expression of the topoisomerase II alpha and beta genes in human breast cancers

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12282-011-0291-4

21 January 2018

Identifiers

10.1007/S12282-011-0291-4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

release_2wmiscstufcffap2linsw7wthu

1 reference

https://api.fatcat.wiki/v0/release/2wmiscstufcffap2linsw7wthu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/21725655

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54577077&oldid=2212525827"